EGFR and non-small cell lung carcinoma: Afatinib is approved in the European Union, USA, Canada, Switzerland, Australia, and several Asian, Latin American, and Middle Eastern countries as an oral, once-daily tablet for patients with non-small-cell lung cancer (NSCLC) and activating EGFR mutations.